Name: | alvimopan |
---|---|
PubChem Compound ID: | 10137178 |
Molecular formula: | C25H32N2O4 |
Molecular weight: | 424.533 g/mol |
Name: | alvimopan |
---|---|
Name (isomeric): | DB06274 |
Drug Type: | small molecule |
Synonyms: |
ADL 8-2698
|
Brand: | Entereg |
Category: | Opiate Antagonists |
CAS number: | 156053-89-3 |
Indication: | Used to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. Also investigated for use in the treatment of pain (acute or chronic). |
---|---|
Mechanism of Action: |
Alvimopan competitively binds to mu-opioid receptor in the gastrointestinal tract. Unlike methylnaltrexone (another peripherally acting mu-receptor antagonist) that bears a quaternary amine, alvimopan owes its selectivity for peripheral receptors to its kinetics. Alvimopan binds to peripheral mu-receptors with a Ki of 0.2 ng/mL and dissociates slow...
show more » |
Absorption: | Alvimopan's high affinity for the peripheral mu-receptor results in an absolute oral bioavailability of less than 7%. |
Protein binding: | 80% to 90% of systemically available alvimopan is bound to plasma protein. |
Biotransformation: | Alvimopan undergoes no significant hepatic metabolism, but is metabolized by intestinal flora. Gut metabolism produces an active metabolite with no clinically significant contribution to drug effect. |
Route of elimination: | Biliary secretion was considered the primary pathway for alvimopan elimination. Unabsorbed drug and unchanged alvimopan resulting from biliary excretion were then hydrolyzed to its ‘metabolite’ by gut microflora. |
Half Life: | 10 to 17 hours (gut metabolite: 10 to 18 hours) |
Clearance: | 402 +/- 89 mL/min |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|